TY - JOUR
T1 - Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer
AU - Fehm, Tanja N
AU - Welslau, Manfred
AU - Müller, Volkmar
AU - Lüftner, Diana
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Thomssen, Christoph
AU - Witzel, Isabell
AU - Beierlein, Milena
AU - Belleville, Erik
AU - Untch, Michael
AU - Thill, Marc
AU - Tesch, Hans
AU - Ditsch, Nina
AU - Lux, Michael P
AU - Aktas, Bahriye
AU - Banys-Paluchowski, Maggie
AU - Kolberg-Liedtke, Cornelia
AU - Hartkopf, Andreas D
AU - Wöckel, Achim
AU - Kolberg, Hans-Christian
AU - Harbeck, Nadia
AU - Stickeler, Elmar
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2023/3
Y1 - 2023/3
N2 - The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.
AB - The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.
UR - http://www.scopus.com/inward/record.url?scp=85150443485&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/fb11c006-8249-3fdd-b2cb-e40e49113b7c/
U2 - 10.1055/a-2018-9053
DO - 10.1055/a-2018-9053
M3 - Scientific review articles
C2 - 36908285
SN - 0016-5751
VL - 83
SP - 289
EP - 298
JO - Geburtshilfe und Frauenheilkunde
JF - Geburtshilfe und Frauenheilkunde
IS - 03
ER -